In Psoriatic Arthritis, Screening for Comorbidities Guides Treatment Selection
A GRAPPA working group highlighted the importance of screening for comorbidities to guide treatment selection among patients with psoriatic arthritis.
Psoriasis Information Center
Adalimumab Plus Methotrexate Promising for Chronic Plaque Psoriasis
The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated.
COVID-19-Related New-Onset and Exacerbated Skin Diseases
Investigators sought to evaluate the association between COVID-19 infection and persistent or new-onset rash following infection.
Updated Psoriatic Arthritis Treatment Recommendations Released
Updated GRAPPA psoriatic arthritis treatment recommendations now include the use of biosimilars and the tapering of therapy.
Methotrexate Access for Autoimmune Diseases in the Post-Roe Setting
AMA president Jack Resneck, Jr., MD, and dermatologist David M. Pariser, MD, FAAD, tell us their thoughts and experiences on the challenges patients face in accessing methotrexate for psoriasis and other autoimmune diseases.
Risankizumab Improves Health-Related Quality of Life in Psoriatic Arthritis
Researchers sought to evaluate the impact of risankizumab vs placebo on health care-related quality of life and other patient-reported outcomes in patients with psoriatic arthritis.
Use of Recommendations for Managing Psoriasis During Pregnancy Varies
A survey reveals the extent of implementation of recommendations for the treatment of psoriasis in patients of reproductive age.
New Fingernail Psoriasis Clinical Outcome Measure is Valid, Reliable
Researchers assessed the validity and reliability of the Physician’s Global Assessment of Fingernail Psoriasis (PGA-F) in the treatment of patients with psoriatic arthritis.
Psoriasis Impacts Characteristics, Treatment of Peripheral Spondyloarthritis
Researchers evaluated the clinical characteristics, disease burden, and treatment of patients with peripheral spondyloarthritis with and without psoriasis.
Diffuse Reflectance Spectroscopy Can Help Assess Psoriasis Severity
Mexameter erythema readings are a good representation of skin oxygenated hemoglobin, but not deoxygenated hemoglobin.
International Experts Urge Uniformity in Methotrexate Dosing for Psoriasis
An international consensus establishes methotrexate dosing recommendations for psoriasis treatment and identifies current knowledge gaps on the topic.
Site of Infection Associated With Increased Risk for PsA and Psoriasis
Researchers evaluated the association between pharyngeal infections and incident psoriatic arthritis and psoriasis.
IL-17 vs TNF Inhibitors for New Biologic Agent Users With Psoriatic Disease
The long-term persistence of various biologic agents in treating psoriasis and psoriatic arthritis are investigated.
Brodalumab Equally Effective in Treating Scalp, Nail Psoriasis in Men and Women
The efficacy of brodalumab by self-identified gender in patients with nail or scalp psoriasis is investigated.
Short-Term Air Pollution May Trigger Psoriasis Flares
Is short-term exposure to air pollutants associated with psoriasis flares?
Rate of Skin Clearance Linked to Quality of Life in Children With Psoriasis
Improvement in psoriasis clearance and its effect on pediatric patients’ quality of life is reviewed.
Top January 2022 FDA Drug Approvals
January 2022 FDA drug approvals include treatments for asthma, psoriatic arthritis, insomnia, and atopic dermatitis.
Modifiable Risk Factors and Cognitive Impairment in Patients With Psoriasis
Potential risk factors associated with cognitive impairment in patients with psoriasis are assessed.
Top August & September 2021 FDA Approvals
August and September 2021 FDA drug approvals include treatments for tick-borne encephalitis, idiopathic hypersomnia, schizophrenia, and atopic dermatitis.
Secukinumab vs Adalimumab in Concomitant PsA and Plaque Psoriasis
Secukinumab vs adalimumab for treatment in patients with concomitant plaque psoriasis and active psoriatic arthritis during 52 weeks is reported.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in News
Loading... 
Loading...